SB 1785, the “No Handouts for Drug Advertisements Act,” would amend the Internal Revenue Code to deny federal income tax deductions for expenses related to direct-to-consumer advertising of certain drugs. The bill applies to advertisements for prescription drug products and compounded drugs, and it defines direct-to-consumer advertising broadly to include television, radio, mail, billboards, internet advertising, social media, mobile apps, and other digital platforms. It excludes advertisements placed in journals and other periodicals.
The bill would create a new Internal Revenue Code section, 280I, making these advertising and promotional costs nondeductible for covered entities, including prescription drug sponsors and owners of outsourcing facilities. The change would apply to amounts paid or incurred after enactment in taxable years ending after enactment, meaning it would take effect immediately for future expenses once signed into law. In practical terms, the measure would increase the tax burden on drug companies that market directly to consumers and would reduce the after-tax value of such advertising expenditures.
Impact
The bill would amend federal tax law by adding a new disallowance rule to the Internal Revenue Code, specifically under Part IX of subchapter B of chapter 1. It would bar deductions for direct-to-consumer advertising expenses tied to covered drugs, thereby changing the tax treatment of pharmaceutical marketing costs. The affected parties would be prescription drug sponsors and operators of outsourcing facilities that advertise prescription or compounded drugs to the general public. The bill would not directly regulate advertising content, but it would use the tax code to discourage such advertising by eliminating the associated deduction.
Sentiment
Based on the bill text and the limited procedural context, the measure appears to be framed as a reform aimed at limiting pharmaceutical advertising incentives, with bipartisan sponsorship from Senator Hawley and Senator Shaheen. There are no recorded committee transcripts or votes in the provided material, so there is no documented floor or committee debate to indicate broader support or opposition. The title and structure suggest a policy approach intended to curb direct-to-consumer drug marketing rather than to expand it.
Contention
The main point of contention is likely the policy choice to penalize pharmaceutical direct-to-consumer advertising through the tax code. Supporters would view the bill as reducing incentives for aggressive drug marketing and potentially lowering consumer exposure to prescription drug ads, while opponents may argue it unfairly targets a lawful business expense and could interfere with commercial speech or marketing practices. Another possible area of dispute is the bill’s broad definition of covered advertising, which includes digital and social media platforms, though it exempts journal and periodical advertising. No specific objections or endorsements are recorded in the provided committee or vote history.